Cover Image

Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA

Introduction - The incidence rate of human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma (OPSCC) is increasing. Despite good prognosis, recurrence can decrease health-related quality of life and increase mortality, so post-treatment monitoring is important for patient outcomes. O...

Full description

Saved in:
Bibliographic Details
Main Authors: Rosing, Fabian (Author) , Plath, Michaela (Author) , Proctor, Tanja (Author) , Höfler, Daniela (Author) , Alt, Yvonne (Author) , Lucena Porcel, Carlota (Author) , Waterboer, Tim (Author) , Heß, Jochen (Author) , Plath, Karim (Author) , Schroeder, Lea (Author)
Format: Article (Journal)
Language:English
Published: April 2025
In: Oral oncology
Year: 2025, Volume: 163, Pages: 1-7
ISSN:1879-0593
DOI:10.1016/j.oraloncology.2025.107225
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.oraloncology.2025.107225
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S1368837525000545
Get full text
Author Notes:Fabian Rosing, Michaela Plath, Tanja Proctor, Daniela Höfler, Yvonne Alt, Carlota Lucena-Porcel, Tim Waterboer, Jochen Hess, Karim Plath, Lea Schroeder
Description
Summary:Introduction - The incidence rate of human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma (OPSCC) is increasing. Despite good prognosis, recurrence can decrease health-related quality of life and increase mortality, so post-treatment monitoring is important for patient outcomes. One potential biomarker for post-treatment monitoring is HPV cell-free DNA (cfDNA) from blood plasma. - Methods - Plasma samples at start of treatment and during follow-up from 27 OPSCC patients were analyzed for cfDNA of six high-risk HPV types using a multiplex digital PCR assay. Presence of HPV cfDNA was compared to HPV tumor status determined by p16INK4a immunohistochemistry, HPV DNA, HPV RNA and HPV16 E6 serology. - Results - At start of treatment, sensitivity of HPV cfDNA detection in HPV-driven OPSCC cases was 89 % (17/19), while specificity was 100 % among 39 plasma samples from 8 HPV-negative OPSCC cases. A median of 4 follow-up plasma samples per patient over a mean time of 11 months were available. Positive and negative predictive values during follow-up were assessed on a per-test-basis. HPV cfDNA testing after completion of therapy had a positive predictive value of 100 % for HPV-OPSCC recurrence within one year, and a negative predictive value of 98 %. In cases of recurrent HPV-driven OPSCC, HPV cfDNA was detectable between 3 and 6.8 months before detection of recurrence by routine follow-up examination methods. - Conclusion - Post-treatment monitoring for early detection of recurrence could be aided by testing for HPV cfDNA in HPV-driven OPSCC patients.
Item Description:Online verfügbar: 05.März 2025
Gesehen am 19.08.2025
Physical Description:Online Resource
ISSN:1879-0593
DOI:10.1016/j.oraloncology.2025.107225

Similar Items